
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
$0.00
1
5
When will the FDA approve Compass Pathways' COMP360 Psilocybin?

$0.00
1
5
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
COMP360 Psilocybin for Treatment-Resistant Depression If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before X 1, 2027, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
AI-generated analysis based on market data. Not financial advice.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

